Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jesse Doty

Orthopaedic Surgery Chattanooga, TN Medical Doctor

NPI 1851513931 CMS profile 84551

979 E. Third Street, Suite C-225, Chattanooga, TN 37403

Open in the dashboard

General payments

$2,255,542

1,147 records reported · program years 2019–2025

Research payments

$1,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$249,394 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jesse Doty of Chattanooga, TN is reported in the CMS Open Payments database as having received $2,255,542 across 1,147 general payments and $1,000 in research payments paid to them. Separately, studies naming them as principal investigator received $249,394 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $578,658 181
2024 General $514,940 180
2023 General $453,833 153
2022 General $174,233 91
2022 Research $1,000 1
2021 General $135,821 90
2020 General $146,807 140
2019 General $251,249 312

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Doty
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jesse Doty were reported at $578,658. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jesse Doty Orthopaedic Surgery median Middle half National median
2019 $251,249 $644 $140–$2,844 $163
2020 $146,807 $312 $75–$1,860 $114
2021 $135,821 $520 $117–$2,495 $132
2022 $174,233 $598 $128–$2,731 $149
2023 $453,833 $461 $128–$2,264 $160
2024 $514,940 $497 $134–$2,475 $164
2025 $578,658 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $830,225 399 payments
  2. Stryker Corporation $591,389 138 payments
  3. Vilex in Tennessee, Inc. $263,942 164 payments
  4. Globus Medical, Inc. $192,829 182 payments
  5. International Life Sciences $152,345 34 payments
  6. Forma Medical $91,367 22 payments
  7. Kuros Biosciences USA, Inc $25,141 17 payments
  8. Novastep Inc. $19,328 14 payments
  9. Extremity Medical $14,984 18 payments
  10. Bone Support Inc. $12,914 13 payments
  11. Other $61,078 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,001,039 118 payments
  2. Consulting Fee $729,472 242 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $333,998 110 payments
  4. Travel and Lodging $168,821 323 payments
  5. Food and Beverage $17,488 347 payments
  6. Education $4,602 5 payments
  7. Gift $86 1 payment
  8. Entertainment $35 1 payment
Products named General payments · program years 2019–2025
  1. Arthrex Foot & Ankle and Trauma - Implants - Core Metal - Bunion - Beveled Screws $761,212 20 payments
  2. ORTHOLOC 2 LAPIFUSE $273,194 24 payments
  3. Arthrex Extremities & Trauma - Implants - Core Metal - Bunion $144,695 4 payments
  4. Arthrex Extremities & Trauma - Implants - Core Metal - Bunion $144,695 4 payments
  5. Arthrex Extremities & Trauma - Implants - Core Metal - Bunion $144,695 4 payments
  6. Arthrex Extremities & Trauma - Implants - Core Metal - Bunion $144,695 4 payments
  7. Arthrex Extremities & Trauma - Implants - Core Metal - Bunion $144,695 4 payments
  8. FLEXBAND $140,804 31 payments
  9. Arthrex Foot & Ankle and Trauma - Implants - Core Metal - Bunion $130,155 4 payments
  10. Arthrex Foot & Ankle and Trauma - Implants - Core Metal - Bunion $130,155 4 payments
  11. Other $1,438,089 742 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Stryker Corporation $1,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

247

Median for Orthopedic Surgery: 203

Drug cost

$5,376

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 221 $5,193
Duloxetine Hcl Generic 15 $138
Gabapentin Generic 11 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$168,520

Of which drugs: $51

Medicare patients

615

Average age 71

Services billed

2,082

414 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 26%
Diabetes 25%
Ischemic heart disease 24%
Chronic kidney disease 22%
Osteoporosis 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 70 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record